When Korea and Japan resumed leaders’ shuttle diplomacy, the pledges were big. Now Seoul is working to make sure the follow-through matches the ambition.

On February 26, Korea’s Ministry of SMEs and Startups (MSS) First Vice Minister Yong-seok Roh spent a packed day in the Tokyo area — visiting a life sciences campus in Fujisawa in the morning and hosting a multi-part pharmaceutical industry event in central Tokyo in the afternoon. The agenda was deliberately practical: move beyond MOU-signing ceremonies and get Korean biotech startups closer to Japanese research partners, investors, and commercial markets.

The morning took Roh to Shonan I-Park in Fujisawa, Japan’s largest private-sector life sciences campus, founded by Takeda Pharmaceutical as an open innovation hub for the global pharma industry. Since inking a cooperation agreement with MSS in November 2023, the campus has taken in 10 Korean biotech ventures under the Global Innovation Special Zone program — giving them lab access, introductions to Japanese pharmaceutical firms, and a base for local market validation.

In his meeting with Shonan I-Park CEO Toshio Fujimoto, Roh focused on what comes next. The two sides agreed to coordinate programs in the lead-up to the opening of Korea’s K-Bio Lab Hub in Songdo, Incheon — a new facility being built on the Yonsei University International Campus, slated for completion in 2028. Once operational, the partnership is expected to deepen into shared equipment use and co-incubation. As an early move, both parties discussed staging the Korean qualifying round of “Innovation Tiger” — an Asia-wide competition that funnels promising biotech startups toward global investors and pharmaceutical companies — at the Songdo site.

Roh also sat down with the 10 Korean startups currently based at Shonan I-Park to hear where they’re running into friction. The recurring themes: navigating Japanese regulatory requirements, converting R&D collaborations into commercial agreements, and securing follow-on funding. Their feedback will feed directly into MSS’s policy planning.

“Shonan I-Park is a clear example of how Korea-Japan bio cooperation can produce tangible outcomes,” Roh said. “We will continue to strengthen policy support so that collaboration on the ground leads to joint research, commercialization, and global market entry.”

From there, Roh visited CIC Tokyo — the Tokyo outpost of Cambridge Innovation Center, which provides not just office space but structured pathways connecting startups with corporations, investors, and public-sector partners. Since the K-Startup Center opened at CIC Tokyo in May 2024, 24 Korean startups have set up there. In his meeting with CEO Tim Rowe, Roh discussed linking CIC Tokyo more formally with K-StartHub, the startup cluster Korea recently opened in Seoul’s Hongdae neighborhood. The planned cooperation would initially center on three sectors — AI, Beauty & Fashion, and Content & Culture — with joint programs designed to build cross-border investment pipelines and business networks.

K-StartHub Opens Applications for Korea’s Largest Startup Incubation Facility 

The afternoon shifted to the Andaz Tokyo, where MSS hosted three back-to-back sessions under the banner of the Global Pharmaceutical & Bio R&D Initiative.

First came the MOU signing. Three major Japanese pharmaceutical companies — Astellas Pharma, Ono Pharmaceutical, and Maruho — each committed to pursue joint R&D projects with Korean biotech SMEs and startups. The mechanics are straightforward: the Japanese firms will specify what they need in terms of new drug technology; MSS will match them with Korean companies capable of delivering it, then provide policy support to push the research toward commercialization. The aim is to skip the prolonged courtship phase that often stalls cross-border pharma partnerships and move directly to co-development.

The 3rd Bio Ecosystem Roundtable followed, drawing in government officials, pharmaceutical companies, venture capital firms, and Korean biotech ventures from both sides. Japan’s Ministry of Economy, Trade and Industry (METI) pointed to growing traction in Japan-Korea pharma partnerships and suggested that tighter ecosystem integration could position Asia as a more significant force in global drug development. One deal cited as a proof point: an October 2025 agreement between Korea’s Youth Bio Global and Japan’s Human Life Cord to run reciprocal clinical trials and pursue commercialization in each other’s markets.

The day closed with a direct matching session — the kind of event that tends to produce the most concrete near-term results. Representatives from Astellas Pharma, Maruho, and Ono Pharmaceutical ran reverse pitches, laying out specific technology needs rather than waiting for startups to guess what they want. Japanese VC firms Global Brain and DCI Partners walked through their investment theses and interest in Korean biotech. Selected Korean startups then pitched back, and received one-on-one briefings on the regulatory and partnership landscape for entering Japan.

“Our objective is clear: joint research must lead to investment and successful commercialization,” Roh said. “We will continue to strengthen institutional and policy support so that companies from both countries can achieve tangible results through collaboration.”

The day’s program reflects a broader calculation: that the gains from Korea-Japan diplomatic warming are only realized if innovation hubs, research campuses, and capital networks are physically and institutionally connected. The groundwork is being laid. Whether it translates into pipelines of jointly developed drugs and globally scaled startups will become clearer over the next few years.